Leishmania eukaryotic elongation Factor-1 beta protein is immunogenic and induces parasitological protection in mice against Leishmania infantum infection

Leishmania infantum amastin protein incorporated in distinct adjuvant systems induces protection against visceral leishmaniasis

(2020) Patrícia A.F. Ribeiro et al.   CYTOKINE

The immunogenicity and protective immunity of multi-epitopes DNA prime-protein  boost vaccines encoding Amastin-Kmp-11, Kmp11-Gp63 and Amastin-Gp63 against visceral leishmaniasis

(2020) Jianhui Zhang et al.   PLoS One

Leishmania infantum pyridoxal kinase evaluated in a recombinant protein and DNA vaccine to protects against visceral leishmaniasis

(2020) João A. Oliveira-da-Silva et al.   MOLECULAR IMMUNOLOGY

New Insights on the Adjuvant Properties of the Leishmania infantum Eukaryotic Initiation Factor

(2019) Olga S. Koutsoni et al.   Journal of Immunology Research

Development and Clinical Evaluation of Loop-Mediated Isothermal Amplification (LAMP) Assay for the Diagnosis of Human Visceral Leishmaniasis in Brazil

(2019) Daniel Moreira de Avelar et al.   Biomed Research International

Recombinant Leishmania eukaryotic elongation factor-1 beta protein: A potential diagnostic antigen to detect tegumentary and visceral leishmaniasis in dogs and humans

(2019) Thaís T.O. Santos et al.   MICROBIAL PATHOGENESIS

Leishmaniasis treatment update of possibilities for drug repurposing

(2018) Eduardo Caio Torres-Santos   Frontiers in Bioscience-Landmark

Vaccination with a CD4 + and CD8 + T-cell epitopes-based recombinant chimeric protein derived from Leishmania infantum proteins confers protective immunity against visceral leishmaniasis

(2018) Daniel S. Dias et al.   Translational Research

Analysis of the Antigenic and Prophylactic Properties of the Leishmania Translation Initiation Factors eIF2 and eIF2B in Natural and Experimental Leishmaniasis

(2018) Esther Garde et al.   Frontiers in Cellular and Infection Microbiology

Liposomal Elongation Factor-1α Triggers Effector CD4 and CD8 T Cells for Induction of Long-Lasting Protective Immunity against Visceral Leishmaniasis

(2018) Abdus Sabur et al.   Frontiers in Immunology

Induction of protective cellular immune responses against experimental visceral leishmaniasis mediated by dendritic cells pulsed with the N-terminal domain of Leishmania infantum elongation factor-2 and CpG oligodeoxynucleotides

(2018) Maria Agallou et al.   MOLECULAR IMMUNOLOGY

Cloning and Recombinant Expression of Elongation Factor-1α of Leishmania mexicana

(2018) Kenia López-López et al.   VECTOR-BORNE AND ZOONOTIC DISEASES

DNA prime-protein boost vaccine encoding HLA-A2, HLA-A24 and HLA-DR1 restricted epitopes of CaNA2 against visceral leishmaniasis

(2018) Jinlei He et al.   IMMUNOLOGY

Cellular Markers of Active Disease and Cure in Different Forms of Leishmania infantum-Induced Disease

(2018) Laura Botana et al.   Frontiers in Cellular and Infection Microbiology

Immunogenicity and protective efficacy of a new Leishmania hypothetical protein applied as a DNA vaccine or in a recombinant form against Leishmania infantum infection

(2018) Patrícia A.F. Ribeiro et al.   MOLECULAR IMMUNOLOGY

Vaccination with poly(D,L-lactide-co-glycolide) nanoparticles loaded with soluble Leishmania antigens and modified with a TNFα-mimicking peptide or monophosphoryl lipid A confers protection against experimental visceral leishmaniasis

(2017) Maritsa Margaroni et al.   International Journal of Nanomedicine

Immuno-informatics based approaches to identify CD8+ T cell epitopes within the Leishmania donovani 3-ectonucleotidase in cured visceral leishmaniasis subjects

(2017) Vijayamahantesh et al.   MICROBES AND INFECTION

Immunization with Leishmania donovani protein disulfide isomerase DNA construct induces Th1 and Th17 dependent immune response and protection against experimental visceral leishmaniasis in Balb/c mice

(2017) Ajay Amit et al.   MOLECULAR IMMUNOLOGY

Inflammatory chemokines and their receptors in human visceral leishmaniasis: Gene expression profile in peripheral blood, splenic cellular sources and their impact on trafficking of inflammatory cells

(2017) Neetu Singh et al.   MOLECULAR IMMUNOLOGY

The Eukaryotic Elongation Factor 1 Alpha (eEF1α) from the Parasite Leishmania infantum Is Modified with the Immunomodulatory Substituent Phosphorylcholine (PC)

(2017) Thomas Timm et al.   MOLECULES

A Poly(Lactic-co-Glycolic) Acid Nanovaccine Based on Chimeric Peptides from Different Leishmania infantum Proteins Induces Dendritic Cells Maturation and Promotes Peptide-Specific IFNγ-Producing CD8+ T Cells Essential for the Protection against Experimental Visceral Leishmaniasis

(2017) Evita Athanasiou et al.   Frontiers in Immunology

Field trial of efficacy of the Leish-tec® vaccine against canine leishmaniasis caused by Leishmania infantum in an endemic area with high transmission rates

(2017) Gabriel Grimaldi et al.   PLoS One

DNA vaccine against visceral leishmaniasis: a promising approach for prevention and control

(2016) A. Kumar et al.   PARASITE IMMUNOLOGY

A recombinant chimeric protein composed of human and mice-specific CD4+and CD8+T-cell epitopes protects against visceral leishmaniasis

(2016) V. T. Martins et al.   PARASITE IMMUNOLOGY

Regulation of immunity during visceral Leishmania infection

(2016) Vasco Rodrigues et al.   Parasites & Vectors

Recent updates and perspectives on approaches for the development of vaccines against visceral leishmaniasis

(2016) Mariana Costa Duarte et al.   Revista da Sociedade Brasileira de Medicina Tropical

Current status on prevention and treatment of canine leishmaniasis

(2016) Rosa M. Reguera et al.   VETERINARY PARASITOLOGY

Prophylactic properties of aLeishmania-specific hypothetical protein in a murine model of visceral leishmaniasis

(2015) D. P. Lage et al.   PARASITE IMMUNOLOGY

Immunological comparison of DNA vaccination using two delivery systems against canine leishmaniasis

(2015) Mehdi Shahbazi et al.   VETERINARY PARASITOLOGY

Kinetoplastid Membrane Protein-11 as a Vaccine Candidate and a Virulence Factor in Leishmania

(2015) Sergio Coutinho Furtado de Mendonça et al.   Frontiers in Immunology

All Human EF1α Promoters Are Not Equal: Markedly Affect Gene Expression in Constructs from Different Sources

(2014) Changyu Zheng et al.   International Journal of Medical Sciences

Identification of Virulence Factors in Leishmania infantum Strains by a Proteomic Approach

(2014) Simone da Fonseca Pires et al.   JOURNAL OF PROTEOME RESEARCH

Th1 Stimulatory Proteins of Leishmania donovani: Comparative Cellular and Protective Responses of rTriose Phosphate Isomerase, rProtein Disulfide Isomerase and rElongation Factor-2 in Combination with rHSP70 against Visceral Leishmaniasis

(2014) Anil Kumar Jaiswal et al.   PLoS One

Visceral Leishmaniasis: Advancements in Vaccine Development via Classical and Molecular Approaches

(2014) Sumit Joshi et al.   Frontiers in Immunology

Efficacy of Leishmania donovani trypanothione reductase, identified as a potent Th1 stimulatory protein, for its immunogenicity and prophylactic potential against experimental visceral leishmaniasis

(2013) Prashant Khare et al.   PARASITOLOGY RESEARCH

Making an anti-amastigote vaccine for visceral leishmaniasis: rational, update and perspectives

(2012) Ana Paula Fernandes et al.   CURRENT OPINION IN MICROBIOLOGY

Phosphorylation of Eukaryotic Elongation Factor 2 (eEF2) by Cyclin A–Cyclin-Dependent Kinase 2 Regulates Its Inhibition by eEF2 Kinase

(2012) Asli A. Hizli et al.   MOLECULAR AND CELLULAR BIOLOGY

Leishmaniasis Worldwide and Global Estimates of Its Incidence

(2012) Jorge Alvar et al.   PLoS One

Elongation Factor-2, a Th1 Stimulatory Protein of Leishmania donovani, Generates Strong IFN-  and IL-12 Response in Cured Leishmania-Infected Patients/Hamsters and Protects Hamsters against Leishmania Challenge

(2011) P. K. Kushawaha et al.   JOURNAL OF IMMUNOLOGY

Mechanisms and consequences of persistence of intracellular pathogens: leishmaniasis as an example

(2008) Christian Bogdan   CELLULAR MICROBIOLOGY

Induction of Th1-type cellular responses in cured/exposed Leishmania-infected patients and hamsters against polyproteins of soluble Leishmania donovani promastigotes ranging from 89.9 to 97.1kDa

(2008) Shraddha Kumari et al.   VACCINE